1. MARKETS
  2. SECTOR : PHARMACEUTICALS & BIOTECHNOLOGY
  3. INDUSTRY : PHARMACEUTICALS
  4. IPCA LABORATORIES LTD.
Ipca Laboratories Ltd.
NSE: IPCALAB | BSE: 524494

Ipca Laboratories Live Share Price Today, Share Analysis and Chart

Strong Performer, Getting Expensive
BasketIn 2 Starfolio Baskets
aboutIpca Laboratories Ltd. is a vertically integrated pharmaceutical company with a significant global presence, specializing in the manufacturing of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms (FDFs). The company maintains a stron... Read More
US FDA Inspections
Ask AI about Ipca Laboratories
1965.5037.70(1.96%)

Near 52W High of ₹2038.00

81,051
NSE+BSE Volume

NSE 02 Nov, 2026 11:30 AM (IST)

Portfolio

Alert

My Notes

Board Meeting
The next board meeting for Ipca Laboratories is on 05 Nov 2026 for the purpose of Quarterly Results See details
Loading...
- / 100
- / 100
65.7 / 100
Strong Performer, Getting ExpensiveThese stocks are strong in quality and technicals but have medium valuation. At somewhat expensive valuations, investors should be cautious before buyingView SimilarEmbed DVM
Analyst Price Target
-

31

S

2

W

6

O

1

T

SWOT Analysis

Check Before You Buy

VIEW FULL CHECKLIST

High rank

18Positive5Negative

Pass in checklist78.3%

045
55
100

PE Valuation Check

Right Now
Undervalued
22.4%
1 Year Forward
Undervalued
42.2%
INSIGHTIpca Laboratories is undervalued at both current PE and future earnings estimates.

Ipca Laboratories Stock Price Analysis

Day Price Range

2.0% 1 Day return
1965.5 (LTP)
1,933.61,969
LowHigh

Week Price Range

0.6% 1 Week return
1965.5 (LTP)
1,910.51,994
LowHigh

Month Price Range

1.2% 1 Month return
1965.5 (LTP)
1,7971,994
LowHigh

52 Week Price Range

54.6% 1 Year return
1965.5 (LTP)
1,2702,038
LowHigh
View full Price History/Seasonality

Ipca Laboratories Forecaster - Analyst Share Price Target and Estimates

Revenue forecast

Hit

Ipca Laboratories's Revenue was higher than average estimate 2 times in past 3 years

EPS forecast

CURRENT EPS
45
AVG. ESTIMATE
59.8
LOW ESTIMATE
54.7
HIGH ESTIMATE
65.4
CURRENT EPS
AVG. ESTIMATE
Hit

EPS is expected to grow by 32.9% in FY27

Consensus Recommendation

17 ANALYST Recommendations
STRONG BUY

The consensus recommendation from 17 analysts for Ipca Laboratories is STRONG BUY

Forecaster is a Premium Feature
You need to upgrade your subscription plan to access this feature
See what you get
Upgrade Now

Ipca Laboratories Technical Analysis

Ipca Laboratories EMA & SMA

Bullish+8
8 bullish, 0 bearish
Bullish8
Bearish0
5 Day1931.5
10 Day1926.7
12 Day1925.8
20 Day1925.7
26 Day1925.3
50 Day1906.7
100 Day1836.3
200 Day1721.7

Ipca Laboratories Delivery And Volume

Daily Avg. Delivery Volume %
30 Oct, 202676.6%
Week60.8%
Month58.6%

Ipca Laboratories Active Candlesticks

Inside Uptrend Shooting Star
Legend
Positive IndicatorNeutral IndicatorNegative Indicator

Ipca Laboratories Resistance and Support

1938.03
Pivot
First Resistance1954.7
Second Resistance1981.5
Third Resistance1998.2
First Support1911.2
Second Support1894.5
Third Support1867.7
Day RSI50.4
Day MACD0.5
Day MFI51.9
Day MACD Signal Line-2.9

Ipca Laboratories Beta

1 Month-0.2
1 Year0.1
3 Month-0.2
3 Year0.4

Ipca Laboratories Price Change Analysis

↑1.2%
Over 1 Month
LowHigh
17971994
↑12.5%
Over 3 Months
LowHigh
1674.42038
↑28.4%
Over 6 Months
LowHigh
14702038
↑54.6%
Over 1 Year
LowHigh
12702038
All Technicals →

Ipca Laboratories Shareholding Pattern/ Ownership

Shareholding Summary

Sep 2026
 
NameCategorySharesShares %
Kaygee Investments Private LimitedPromoter64,665,44825.5 %
Kotak Mutual FundsFii2,730,0001.1 %
Hdfc Mutual FundDii24,124,9179.5 %

HISTORICAL PROMOTER HOLDING

HISTORICAL FII HOLDING

HISTORICAL MF HOLDING

All Shareholding details

Ipca Laboratories Deals - Insider, Bulk, Block and SAST

Client NameDeal TypeActionDateAvg. PriceQuantityExchange
USHA MADHUKAR CHANDURKARBulkSell18 Dec 20241501.524,000,000BSE
ISHARES CORE EMERGING MARKETS MAURITIUS COBlockSell14 Nov 2022867.55158,841NSE
ISHARES CORE MSCI EMERGING MARKETS ETFBlockPurchase14 Nov 2022867.55158,841NSE
ISHARES CORE EMERGING MARKETS MAURITIUS COBlockSell03 Nov 2022927.15158,842NSE
ISHARES CORE MSCI EMERGING MARKETS ETFBlockPurchase03 Nov 2022927.15158,842NSE
ISHARES INDIA SC MAURITIUS COMPANYBlockSell25 Oct 2022900.3568,372BSE
ISHARES CORE EMERGING MARKETS MAURITIUS COBlockSell25 Oct 2022900.35148,105BSE
ISHARES MSCI INDIA SMALL-CAP ETFBlockPurchase25 Oct 2022900.3568,372BSE
ISHARES CORE MSCI EMERGING MARKETS ETFBlockPurchase25 Oct 2022900.35148,105BSE
ISHARES INDIA SC MAURITIUS COMPANYBlockSell17 Oct 2022889.4534,160BSE
All deals
All insider trades

Ipca Laboratories Corporate Actions

Ipca Laboratories Dividend history and yield

Ipca Laboratories dividend yields, including actual and adjusted, and dividend history, including announcement, record, and ex-dividend dates. Track Ipca Laboratories dividend yield over time.

#Ex-Date
Dividend AmountDividend TypeRecord DateInstrument Type
107 Aug 2026
6FINAL07 Aug 2026Equity Share
205 Aug 2025
2FINAL05 Aug 2025Equity Share
325 Nov 2024
2INTERIM25 Nov 2024Equity Share
406 Aug 2024
2FINAL-Equity Share
522 Nov 2023
2INTERIM22 Nov 2023Equity Share

Ipca Laboratories Bonus shares

Ipca Laboratories bonus history along with announcement, record, ex-bonus dates, and bonus ratios.

#Ex-Date
Bonus RatioRecord Date
128 Jan 2005
1:131 Jan 2005

Ipca Laboratories Board Meetings

Ipca Laboratories past and upcoming board meetings.

#Ex-Date
PurposeNotes
105 Nov 2026
Quarterly Results-
213 Aug 2026
Quarterly Results-
329 May 2026
Audited Results & Dividend-
413 Feb 2026
Quarterly Results-
513 Nov 2025
Quarterly Results-

Ipca Laboratories Stock Split

Ipca Laboratories stock split details, including announcement, record, and ex-split dates, along with the split ratios

#Ex-Date
Old FVNew FVRecord Date
110 Jan 2022
2111 Jan 2022
222 Mar 2010
10223 Mar 2010
All Corporate Actions

Ipca Laboratories Research Reports

Ipca Laboratories research reports with share price targets, and buy/hold/sell recommendations from top brokers.

#
Date
Broker NameTargetPrice When RecommendedTypeUpsideChange Since RecommendationLinks
116 Aug 2026Emkay
Target
19501734.2Buy12.44%13.34%pdf
213 Aug 2026Motilal Oswal
Target
20601734.2Buy18.79%13.34%pdf
301 Jun 2026Prabhudas Lilladhar18001507.7Buy19.39%30.36%pdf
401 Jun 2026Emkay18001507.7Buy19.39%30.36%pdf
501 Jun 2026ICICI Direct
Target
18451507.7Buy22.37%30.36%pdf
All Reports of Ipca

Ipca Laboratories Corporate Filings

Ipca Laboratories BSE corporate filings and AGM, press releases, insider trading & SAST, results and corporate actions.

DateAnnouncement TitleDetailsLinks
28 Oct 2026
Ipca Laboratories Ltd - 524494 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Schedule of Conference Call
PDF
22 Oct 2026
Ipca Laboratories Ltd - 524494 - Board Meeting Intimation for Standalone And Consolidated Unaudited Financial Results For The Second Quarter And Half Year Ended 30.09.2026
Ipca Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/11/2026 ,inter alia, to consider and approve Standalone and Consolidated Unaudited Financial Results for the second quarter and half year ended 30.09.2026
PDF
12 Oct 2026
Ipca Laboratories Ltd - 524494 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
The Company has enclosed herewith certificate recived from RTA under reg 74 5 for the quarter ended 30.09.2026.
PDF
22 Sep 2026
Ipca Laboratories Ltd - 524494 - Closure of Trading Window
Closure of Trading Window
PDF
17 Aug 2026
Ipca Laboratories Ltd - 524494 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Transcript of Conference Call
PDF
VIEW ALL

Ipca Laboratories DocumentsAsk MarketMind AI

Ipca Laboratories Earnings Call

Ipca Laboratories earnings calls, including management commentary and AI-generated summaries.

DateTitleLinks
17 Aug 2026Ipca Laboratories Ltd - 524494 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeLink
14 Aug 2026Ipca Laboratories Results Earnings Call for Q1FY27AudioVideo
16 Feb 2026Ipca Laboratories Results Earnings Call for Q3FY26AudioVideo
13 Nov 2025Ipca Laboratories Results Earnings Call for Q2FY26AudioVideo
12 Aug 2025Ipca Laboratories Results Earnings Call for Q1FY26AudioVideo
view all

Ipca Laboratories Annual Reports

Ipca Laboratories financials, including annual results, balance sheets, and cash flow statements.

DateReport TitleLinks
2026Annual Report Mar-2026Link
2025Annual Report Mar-2025Link
2024Annual Report Mar-2024Link
2022Annual Report Mar-2022Link
2021Annual Report Mar-2021Link

Ipca Laboratories Credit Ratings

Ipca Laboratories credit ratings from CRISIL and leading rating agencies, assessing financial stability, investment grade, and related PDF documentation.

DateRating AgencyCompany NameDescriptionLinks
05 Jul 2026india ratingsIndia Ratings Affirms Ipca Laboratories’ Bank Facilities at ‘IND AA+’/Stable and CP at ‘IND A1+’Link
06 Jul 2025india ratingsIndia Ratings Affirms Ipca Laboratories’s Bank Facilities at ‘IND AA+’/Stable; CP at ‘IND A1+’Link
26 Jul 2023india ratingsIndia Ratings Affirms Ipca Laboratories ‘IND AA+’/Stable; Limits EnhancedLink
24 Jul 2023india ratingsCorrection: India Ratings Assigns Ipca Laboratories ‘IND AA+’/StableLink
17 Oct 2022care ratingsIPCA Laboratories LimitedLink

Ipca Laboratories - Company Profile

Ipca Laboratories Management Structure

Ipca Laboratories management structure with salaries, total experience, and qualifications.

NAMEDESIGNATIONGROSS REMUNERATION ₹(LAC)AS OFHISTORY & DETAILS
A K JainExecutive Director.(Professional.),Managing Director,Chief Financial Officer,Non Promoter1060.21Mar 26
Pranay GodhaExecutive Director,Managing Director,Chief Executive Officer978.28Mar 26
Harish P KamathCompany Secretary,Corporate Counsel250.04Mar 26
Premchand GodhaExecutive Chairman-Mar 26
Prashant GodhaExecutive Director-Mar 26
Dr. Ashok KumarPresident(R & D,Chemicals.)-Mar 26
Dr. Anil PareekPresident(Medical Affairs)-Mar 26
Mr. Sunil GhaiPresident(Marketing Support)-Mar 26
Mr. Pabitra Kumar BhattacharyaPresident(Operations)-Mar 26
Dr. Sanjay KapadiaPresident(Corporate Quality Assurance)-Mar 26
Ms. Kavita SehwaniPresident(Generics)-Mar 26
Mr. Shashil MendonsaPresident(International Marketing)-Mar 26
Mr. Shailesh LaulPresident(Operations,Formulations)-Mar 26
Mr. Hitesh MaheshwariPresident(R & D,Formulations)-Mar 26
Mr. Saidutta NandaPresident(Human Resources)-Mar 26
Dr. Nagaji VekariyaPresident(API.)-Mar 26

Ipca Laboratories Board of Directors

Ipca Laboratories Board of directors with salaries, total experience, and qualifications.

NAMEPOSITIONGROSS REMUNERATION ₹(LAC)AS OFHISTORY & DETAILS
Premchand GodhaChairman/ED & CEO1496.51Mar 26
A K JainED/MD/CFO/NP1060.21Mar 26
Pranay GodhaED / MD / CEO / Promoter995.08Mar 26
Prashant GodhaExecutive Director718.85Mar 26
Harish P KamathCompany Secretary / Corporate Counsel250.04Mar 26
Kamal Kishore SethIndependent Non Exe. Director14.5Mar 26
Vivek ShiralkarIndependent Non Exe. Director12.5Mar 26
Narendra MairpadyIndependent Non Exe. Director11.5Mar 26
Swati PatankarIndependent Non Exe. Director9.5Mar 26

Ipca Laboratories Brands

Brands owned by Ipca Laboratories

LOGOBRAND NAME
Adalipca
Azibact
Keraglo AD
Ace Revelol
LOGOBRAND NAME
CutiYt Total
Divalrate ER
Donica
Drolgan
LOGOBRAND NAME
Malirid
Metagard
Mirbeg
Mirbeg S
LOGOBRAND NAME
Saaz
Solvin Nasal Spray
Solvin Cough
Solvin Decongestant
Website: www.ipca.com

About the company - Business Profile

Ipca Laboratories Ltd. is a vertically integrated pharmaceutical company with a significant global presence, specializing in the manufacturing of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms (FDFs). The company maintains a strong market position in therapeutic segments such as pain management, rheumatology, antimalarials, and cardiovascular health. It operates as a key player in both the Indian domestic market and international generics, with exports contributing a substantial portion of its total revenue.

Key Points

  • Key Facts: Founded in 1949 and headquartered in Mumbai, Maharashtra, Ipca Laboratories is listed on both the BSE (Scrip Code: 524494) and the NSE (Scrip Code: IPCALAB).
  • Operations and Resources: The company manages multiple manufacturing facilities across India. It is vertically integrated, producing over 50 APIs and a wide range of formulations. Its Research & Development (R&D) centers in Mumbai focus on both chemical (APIs) and formulation development.
  • Ownership: The company is led by Executive Chairman Premchand Godha, with Pranay Godha serving as Managing Director and CEO.
  • Market and Significance: Ipca serves various therapeutic areas including anti-infectives, gastrointestinal, and anti-diabetics. It holds a leading position in the antimalarial segment globally.

Business Model and Core Competencies Ipca’s business model centers on vertical integration, allowing it to control the supply chain from basic chemical stages to finished dosages. This integration provides a competitive edge in cost management and quality control. The company excels in high-volume production of complex generic molecules and maintains a robust domestic distribution network.

Financial Performance (FY 2024-25)

  • Total Income: ₹6,749.21 crore, representing a growth from ₹6,277.75 crore in the previous year.
  • Revenue Breakdown by Segment:
    • Domestic Income: ₹3,940.25 crore (approx. 58% of total income).
    • Export Income: ₹2,808.96 crore (approx. 42% of total income).
  • Profitability:
    • EBITDA: ₹1,584.62 crore.
    • Net Profit (PAT): ₹650.76 crore.
    • Earnings Per Share (EPS): ₹25.65.
  • Interim Performance (H1 FY26): Consolidated revenue reached ₹4,865.35 crore for the first half of the 2025-26 fiscal year, with a 9% year-on-year growth.

Key Products and Technology The company focuses on a diverse product portfolio, with notable presence in:

  • Pain Management: Leading brands like Zerodol (Aceclofenac).
  • Antimalarials: Production of Artemisinin-based Combination Therapies (ACTs).
  • Cardiovascular: Products such as CTD (Chlorthalidone) and Revelol (Metoprolol).
  • R&D Advancements: Continued investment in R&D, focusing on specialty molecules and expanding the API portfolio to reduce dependence on external suppliers.

Organizational Structure and Initiatives

  • Subsidiaries: Major subsidiaries include Unichem Laboratories Ltd. (acquired for strategic expansion), Lyka Labs Ltd., and Ipca Pharma (Australia) Pty Ltd.
  • Strategic Initiatives: Current focus includes enhancing operational efficiencies at recently acquired facilities, expanding the branded formulations business in emerging markets, and increasing the contribution of specialty products.
  • Sustainability: The company emphasizes "Responsibility, Dignity, Integrity, Quality, and Safety" as core values, though specific quantifiable net-zero targets were not detailed in the brief highlights beyond corporate governance adherence.

References

  1. Annual Report May 2025
  2. Annual Report May 2024
  3. Results Nov 2025
  4. Results Feb 2026

Ipca Laboratories FAQ

Ipca Laboratories today is trading in the green, up by 1.96% at ₹1,965.5.
Ipca Laboratories is currently trading up 1.96% on an intraday basis. In the past week the stock rose 0.62%. Stock has been up 12.46% in the past quarter and rose 54.62% in the past year. You can view this in the share price history/seasonality section.
Ipca Laboratories is listed on NSE with the ticker IPCALAB and on BSE as 524494. It's currently trading on NSE at a share price of ₹1,965.5 and on BSE with a share price of ₹1,965.6.
The market cap of Ipca Laboratories is ₹49,865.56 Cr. as of Nov 02, 2026.
Ipca Laboratories announced a FINAL dividend of 600% which equals ₹6 in Aug 07, 2026.The last three ex-dates for Ipca Laboratories were Aug 05, 2025, Nov 25, 2024 and Aug 06, 2024. To view the full dividend history of Ipca Laboratories click here.
Ipca Laboratories has undergone 2 stock splits and announced bonus shares 1 time since its BSE/NSE listing. The latest announcement for Ipca Laboratories stock split was on Jan 10, 2022 at a ratio of 2:1 and the last bonus share announcement was on Jan 28, 2005 at a ratio of 1:1.
Ipca Laboratories reported ₹2,813.36 Cr. in revenue, ₹401.89 Cr. in net profit, and ₹694.77 Cr. in EBITD as of Aug 13, 2026 for Q1 FY26-27.
According to the predictions of 18 analysts, the share price prediction for Ipca Laboratories is ₹1,981.72 with an upside of 1%.
The PE ratio of Ipca Laboratories is 38.07 as of Nov 02, 2026.
The PB ratio of Ipca Laboratories is 5.88 as of Nov 02, 2026.
You can view the latest analyst reports on the Ipca Laboratories reports dashboard. Either click on the Reports tab on this page's sub-header or click here to be directed to the dashboard.
You can set real-time stock alerts on price, volume, SMA, and several other parameters by scrolling to the top of this page and clicking the bell icon on the far right-hand side of the stock overview.
Ask AI
×